Price
No data yet.
Social Signal Score
Analyst Ratings
11 analystsRevenue
$114.44M+196.42%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Katherine A. Stueland
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Employees
- 1,300
- Beta
- 2.01
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 1.93
Financials
Revenue
$114.44M+196.4%Net Income
$-17.74MEBITDA
$-10.36MFree Cash Flow
$-39.09MEPS (diluted)
$-0.60Shares Outstanding (diluted)
29.71M+428.0%Operating Expenses
$95.69MCash & Debt
$132.55MRevenue by Segment (annual)
$844.21MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $427.54M | $-21.02M | $-0.73 |
| 2024 | $305.45M | $-52.29M | $-1.94 |
| 2023 | $202.57M | $-175.77M | $-7.23 |
| 2022 | $234.69M | $-548.98M | $-53.63 |
| 2021 | $212.19M | $-245.39M | $-74.93 |
| 2020 | $179.32M | $-241.34M | $-33.16 |
| 2019 | $196.17M | $-29.70M | $-4.26 |
Valuation
WGShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100-3.23%Social Signal Score
Mentions (3)
- Newsbusinesswire.com·4d ago·Neutral
GeneDx Introduces Easy Order at AAP 2026 to Simplify Genomic Testing in Everyday Pediatric Care GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx introduces Easy Order at AAP 2026 to simplify genomic testing in everyday pediatric care.
View source ↗ - Newszacks.com·47d ago·Neutral
Can GENEDX HOLDINGS (WGS) Run Higher on Rising Earnings Estimates? GeneDx Holdings Corp. (WGS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
View source ↗ - Newsseekingalpha.com·48d ago·Neutral
GeneDx: Why I Think The Worst Is Behind The Business GeneDx shows early signs of operational recovery, with Q2 revenue and margins exceeding expectations and testing volumes up 32%. Reimbursement rates have stabilized, and management expects meaningful improvements in Q4 and a stronger recovery in 2027. Valuation remains attractive, with a Buy rating maintained. Upside potential exists if reimbursement and growth targets are met.
View source ↗
Earnings
Tue, Oct 27(in 3 weeks)
Consensus estimate $0.07 per share
Typical surprise +105.3% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 3$0.01 vs $-0.19beat
- Mon, May 4$-0.28 vs $-0.06miss
- Mon, Feb 23$0.14 vs $0.11beat
- Tue, Oct 28$0.49 vs $0.28beat
- Tue, Jul 29$0.50 vs $0.10beat
- Wed, Apr 30$0.28 vs $0.11beat
Estimates and results for WGS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by WGS officers and directors.
- Bought
- $93.1m
- Sold
- $3.6m
27 trades
28 trades
- Stueland Katherinesold
- Stueland Katherinesold
- Stueland Katherinesold
- Stueland Katherinesold
- Stueland Katherinesold
- Feeley Kevinsold
- Feeley Kevinsold
- Feeley Kevinsold
45 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in WGS.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.